Adaptive Biotechnologies Q1 2026: MRD Momentum Fuels Revenue Growth and a Raised Revenue Forecast

Executive snapshot

Adaptive Biotechnologies Corp (ADPT) posted a first quarter of 2026 that leaned heavily on MRD (minimal residual disease) programs, with revenue of $70.9 million for the quarter ended March 31, 2026. MRD revenue accounted for $67.1 million of that total, up 53% from the prior year, while Immune Medicine revenue was $3.8 million. Notably, revenue excluding Genentech-related activity rose 45% year over year, underscoring the MRD-driven growth engine even as collaboration revenue fades from the top line.

The quarter produced a net loss of $20.0 million, versus a $29.8 million loss in the prior-year period. Operating expenses rose about 10% to $90.1 million. After interest and other income of $2.1 million and steady interest expense from a revenue interest purchase agreement at $2.9 million, the company’s quarterly profitability remains a work in progress, a familiar refrain for a growth-stage bet on precision diagnostics and biotech-enabled drug development.

MRD as the growth engine and product cadence

A few lines in the sand for ADPT: MRD is not just a product line; it’s the growth narrative. The clonoSEQ test volume rose to 32,595 tests delivered in the quarter, reflecting continued uptake in the diagnostic lab and monitoring workflows. Management highlighted that MRD revenues were the primary driver of the quarterly top line, contributing 95% of revenue, with the Genentech agreement no longer generating revenue in Q1 2026 (a reminder that the external collaboration tailwind can fade even as core products gain steam).

The company also disclosed a $9.0 million MRD pharma regulatory milestone revenue, signaling that regulatory milestones remain a meaningful, near-term source of revenue in addition to routine test volumes. In a market where “revenue forecast” clarity matters, ADPT raised its full-year MRD revenue guidance to a range of $260 million to $270 million, implying roughly 22% to 27% annual growth for MRD in 2026.

Management commentary and tone

In a statement that lands somewhere between confident and pragmatic, Chad Robins, chief executive officer and co-founder, framed the quarter as a validation of the company’s strategy: “We delivered strong first quarter results based on accelerating adoption of MRD across both clinical testing and drug development. Our performance reinforces our market leadership position and the differentiated value of our platform.”

The forward-looking stance is explicit: the MRD trajectory, supported by multiple growth drivers, positions Adaptive to sustain its growth path and create long-term value. The language echoes a willingness to trade near-term profitability for expansion of the MRD ecosystem, a common calculus for a company balancing lab diagnostics expansion with platform-scale deals.

Detailed quarter highlights

• Revenue: $70.9 million for the quarter; MRD revenue: $67.1 million; Immune Medicine revenue: $3.8 million.
• MRD growth: 53% year over year; clonoSEQ test volume: 32,595 tests delivered in Q1 2026 (growth metrics implied but not headline-numbered in the release).
• Genentech impact: Excluding Genentech revenue, total quarterly revenue grew 45% YoY.
• Net loss: $20.0 million; prior-year quarter net loss: $29.8 million; excluding Genentech revenue, the comparable metric in 2025 would be higher, underscoring how much the Genentech collaboration had previously supported the reported baseline.
• Operating expenses: $90.1 million (up 10% YoY).
• Interest and other income: $2.1 million; Interest expense: $2.9 million from the revenue interest purchase agreement (consistent with the prior year).
• Milestones and strategy: $9.0 million in MRD pharma regulatory milestone revenue.

What this portends for Adaptive and sector peers

The quarter’s narrative centers on MRD as a growth engine rather than a single product line. For Adaptive, the trajectory hinges on deepening adoption of MRD in both clinical testing and drug development, while continuing to monetize regulatory milestones. The absence of Genentech revenue in Q1 2026 removes one-time support from the top line, making the MRD core more consequential to the revenue forecast and investor confidence.

For sector peers, the quarter reinforces a broader trend: MRD-centric platforms are transitioning from niche offerings to strategic enablers of precision medicine. If ADPT’s raised MRD revenue guidance holds, it may elevate guidance discipline across the sector and put pressure on competitors to demonstrate comparable MRD test volumes and milestone-rich revenue streams.

The balance sheet narrative remains a key watch: ongoing operating expenditures and the path to EBITDA profitability depend on sustained MRD demand, pricing dynamics, and the ability to convert test volume into durable recurring revenue. In the near term, investors will scrutinize how management translates a rising test volume into cost discipline and margin expansion while continuing to fund product development and pipeline expansion.

Strategic takeaways and risks

Takeaways: ADPT’s decision to lift the MRD revenue forecast signals conviction in the MRD trajectory and a willingness to lean into revenue growth before broad-scale profitability. The MRD program’s robust growth, combined with milestone revenues, creates a more diverse revenue mix than a pure services or instrument-play would offer. Still, the company’s overall bottom line remains a work in progress, with net losses and rising operating expenses likely to persist into 2026 as the MRD business scales.

Risks to watch include: whether MRD volumes sustain their growth rate in a potentially more competitive landscape, how regulatory milestones translate into cash, and how dependence on large collaboration structures (like the Genentech arrangement) evolves as partnerships mature or contract terms shift. The absence or renegotiation of partner-driven revenue would be a meaningful swing factor for both EPS-related metrics and the EPS consensus trajectory among analysts.

Bottom line

Adaptive Biotechnologies’ Q1 2026 results underscore a company that is leaning into a growth thesis built on MRD leadership. A higher revenue forecast for the MRD segment, a credible cadence of milestones, and a disciplined cost base will be the levers investors watch as the year unfolds. Whether the market assigns a higher multiple to a company with steady MRD momentum or remains cautious on the path to profitability will hinge on quarterly receipts of EPS-like signals, the evolution of the EPS consensus for the company, and how effectively ADPT can convert test volume growth into sustained cash flow.